Deans' stroke musings: Michael J. Fox Foundation awards $468K to therapeutics developer

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Saturday, March 10, 2012

Michael J. Fox Foundation awards $468K to therapeutics developer

Another example of what a good stroke association should look like. If you are a stroke board member contact me.
http://www.medcitynews.com/2012/03/michael-j-fox-foundation-awards-468k-to-therapeutics-developer/
A drug developer has received $468,000 from the Michael J. Fox Foundation for its Parkinson’s disease therapeutic.

QR Pharma is collaborating with Dr. Robert Nussbaum of the Division of Medical Genetics at the University of California, San Francisco and Dr. Jack T. Rogers of Massachusetts General Hospital, Genetics and Aging Research Unit on its therapeutic, Prosiphen, according to a company statement.

The funding was allocated to QR Pharma as part of the foundation’s Therapeutics Development Initiative for preclinical research for Parkinson’s disease.

QR Pharma CEO Maria Maccecchini is a serial entrepreneur and her company is based in Berwyn, Pennsylvania.

Prosiphen will be used in studies with mice at San Francisco to determine its effectiveness in mice in reversing gastrointestinal difficulties and motor abnormalities, symptoms similar to what are found in people with Parkinson’s disease. The tests will help establish preclinical efficacy as a basis for future testing in humans, a statement from QR Pharma said.

In addition to Parksinson’s disease, Prosiphen is one of two compounds QR Pharma is developing to treat Alzheimer’s disease.

Last year, Maccecchini received the Iris Newman award from the Alliance of Women Entrepreneurs.

The Michael J. Fox Foundation has contributed $275 million to fund research to develop a cure and treat Parkinson’s disease. In February, it launched a partnering program to highlight encouraging research results in the foundation’s portfolio to attract funders to foster development to help drive research projects through the product pipeline.